Treatment of mucocutaneous manifestations in Behcets disease with anakinra: a pilot open-label study

Background The effect of IL-1 blocking therapy on mucocutaneous manifestations of Behcet’s disease is incompletely understood. Methods Six patients with Behcet’s disease and ongoing oral/genital ulcers for ≥1 month were enrolled into an adaptive, two-phase clinical trial and included in the analysis. Study duration was 6 months with extension up to 16 months. All were treated non-blinded with anakinra 100 mg subcutaneous daily with the option to escalate the dose to 200 mg in partial responders after 1 month and 300 mg after 6 months. Patients recorded the number and severity of ulcers in dail... Mehr ...